The global market for PD-1 and PD-L1 Inhibitor was valued at US$ 117 million in the year 2024 and is projected to reach a revised size of US$ 181 million by 2031, growing at a CAGR of 6.6% during the forecast period.

PD-1 and PD-L1 Inhibitor Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Inhibitor.

The PD-1 and PD-L1 Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-1 and PD-L1 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the PD-1 and PD-L1 Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of PD-1 and PD-L1 Inhibitor Market Report

Report Metric	Details
Report Name	PD-1 and PD-L1 Inhibitor Market
Accounted market size in year	US$ 117 million
Forecasted market size in 2031	US$ 181 million
CAGR	6.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Monoclonal Antibody Bispecific Antibody
Segment by Application	Lung Cancer Stomach Cancer Breast Cancer Rectal Cancer Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merck, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Roche, AstraZeneca, Bristol Myers Squibb, Hengrui Medicine, Beigene, Innovent Biologics, Junshi Biosciences, Akeso, Alphamab Oncology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PD-1 and PD-L1 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is PD-1 and PD-L1 Inhibitor Market growing?

Ans: The PD-1 and PD-L1 Inhibitor Market witnessing a CAGR of 6.6% during the forecast period 2025-2031.

What is the PD-1 and PD-L1 Inhibitor Market size in 2031?

Ans: The PD-1 and PD-L1 Inhibitor Market size in 2031 will be US$ 181 million.

Who are the main players in the PD-1 and PD-L1 Inhibitor Market report?

Ans: The main players in the PD-1 and PD-L1 Inhibitor Market are Merck, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Roche, AstraZeneca, Bristol Myers Squibb, Hengrui Medicine, Beigene, Innovent Biologics, Junshi Biosciences, Akeso, Alphamab Oncology

What are the Application segmentation covered in the PD-1 and PD-L1 Inhibitor Market report?

Ans: The Applications covered in the PD-1 and PD-L1 Inhibitor Market report are Lung Cancer, Stomach Cancer, Breast Cancer, Rectal Cancer, Others

What are the Type segmentation covered in the PD-1 and PD-L1 Inhibitor Market report?

Ans: The Types covered in the PD-1 and PD-L1 Inhibitor Market report are Monoclonal Antibody, Bispecific Antibody

1 PD-1 and PD-L1 Inhibitor Market Overview

1.1 Product Definition

1.2 PD-1 and PD-L1 Inhibitor by Type

1.2.1 Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Type (2024 VS 2031)

1.2.2 Monoclonal Antibody

1.2.3 Bispecific Antibody

1.3 PD-1 and PD-L1 Inhibitor by Application

1.3.1 Global PD-1 and PD-L1 Inhibitor Market Value by Application (2024 VS 2031)

1.3.2 Lung Cancer

1.3.3 Stomach Cancer

1.3.4 Breast Cancer

1.3.5 Rectal Cancer

1.3.6 Others

1.4 Global PD-1 and PD-L1 Inhibitor Market Size Estimates and Forecasts

1.4.1 Global PD-1 and PD-L1 Inhibitor Revenue 2020-2031

1.4.2 Global PD-1 and PD-L1 Inhibitor Sales 2020-2031

1.4.3 Global PD-1 and PD-L1 Inhibitor Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 PD-1 and PD-L1 Inhibitor Market Competition by Manufacturers

2.1 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2020-2025)

2.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2020-2025)

2.3 Global PD-1 and PD-L1 Inhibitor Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of PD-1 and PD-L1 Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Product Type & Application

2.7 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Date of Enter into This Industry

2.8 Global PD-1 and PD-L1 Inhibitor Market Competitive Situation and Trends

2.8.1 Global PD-1 and PD-L1 Inhibitor Market Concentration Rate

2.8.2 The Global 5 and 10 Largest PD-1 and PD-L1 Inhibitor Players Market Share by Revenue

2.8.3 Global PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global PD-1 and PD-L1 Inhibitor Market Scenario by Region

3.1 Global PD-1 and PD-L1 Inhibitor Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2020-2031

3.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2020-2025

3.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2026-2031

3.3 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2020-2031

3.3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2020-2025

3.3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2026-2031

3.4 North America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country

3.4.1 North America PD-1 and PD-L1 Inhibitor Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)

3.4.3 North America PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country

3.5.1 Europe PD-1 and PD-L1 Inhibitor Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)

3.5.3 Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific PD-1 and PD-L1 Inhibitor Market Facts & Figures by Region

3.6.1 Asia Pacific PD-1 and PD-L1 Inhibitor Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region (2020-2031)

3.6.3 Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country

3.7.1 Latin America PD-1 and PD-L1 Inhibitor Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)

3.7.3 Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country

3.8.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)

3.8.3 Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2020-2031)

4.1.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2020-2025)

4.1.2 Global PD-1 and PD-L1 Inhibitor Sales by Type (2026-2031)

4.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2020-2031)

4.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2020-2031)

4.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2020-2025)

4.2.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2026-2031)

4.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2020-2031)

4.3 Global PD-1 and PD-L1 Inhibitor Price by Type (2020-2031)

5 Segment by Application

5.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2020-2031)

5.1.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2020-2025)

5.1.2 Global PD-1 and PD-L1 Inhibitor Sales by Application (2026-2031)

5.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2020-2031)

5.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2020-2031)

5.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2020-2025)

5.2.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2026-2031)

5.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2020-2031)

5.3 Global PD-1 and PD-L1 Inhibitor Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Merck

6.1.1 Merck Company Information

6.1.2 Merck Description and Business Overview

6.1.3 Merck PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio

6.1.5 Merck Recent Developments/Updates

6.2 Bristol-Myers Squibb

6.2.1 Bristol-Myers Squibb Company Information

6.2.2 Bristol-Myers Squibb Description and Business Overview

6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio

6.2.5 Bristol-Myers Squibb Recent Developments/Updates

6.3 Pfizer

6.3.1 Pfizer Company Information

6.3.2 Pfizer Description and Business Overview

6.3.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio

6.3.5 Pfizer Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Company Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Regeneron Pharmaceuticals

6.5.1 Regeneron Pharmaceuticals Company Information

6.5.2 Regeneron Pharmaceuticals Description and Business Overview

6.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio

6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates

6.6 Roche

6.6.1 Roche Company Information

6.6.2 Roche Description and Business Overview

6.6.3 Roche PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio

6.6.5 Roche Recent Developments/Updates

6.7 AstraZeneca

6.7.1 AstraZeneca Company Information

6.7.2 AstraZeneca Description and Business Overview

6.7.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.7.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio

6.7.5 AstraZeneca Recent Developments/Updates

6.8 Bristol Myers Squibb

6.8.1 Bristol Myers Squibb Company Information

6.8.2 Bristol Myers Squibb Description and Business Overview

6.8.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio

6.8.5 Bristol Myers Squibb Recent Developments/Updates

6.9 Hengrui Medicine

6.9.1 Hengrui Medicine Company Information

6.9.2 Hengrui Medicine Description and Business Overview

6.9.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio

6.9.5 Hengrui Medicine Recent Developments/Updates

6.10 Beigene

6.10.1 Beigene Company Information

6.10.2 Beigene Description and Business Overview

6.10.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio

6.10.5 Beigene Recent Developments/Updates

6.11 Innovent Biologics

6.11.1 Innovent Biologics Company Information

6.11.2 Innovent Biologics Description and Business Overview

6.11.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio

6.11.5 Innovent Biologics Recent Developments/Updates

6.12 Junshi Biosciences

6.12.1 Junshi Biosciences Company Information

6.12.2 Junshi Biosciences Description and Business Overview

6.12.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio

6.12.5 Junshi Biosciences Recent Developments/Updates

6.13 Akeso

6.13.1 Akeso Company Information

6.13.2 Akeso Description and Business Overview

6.13.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio

6.13.5 Akeso Recent Developments/Updates

6.14 Alphamab Oncology

6.14.1 Alphamab Oncology Company Information

6.14.2 Alphamab Oncology Description and Business Overview

6.14.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio

6.14.5 Alphamab Oncology Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 PD-1 and PD-L1 Inhibitor Industry Chain Analysis

7.2 PD-1 and PD-L1 Inhibitor Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 PD-1 and PD-L1 Inhibitor Production Mode & Process Analysis

7.4 PD-1 and PD-L1 Inhibitor Sales and Marketing

7.4.1 PD-1 and PD-L1 Inhibitor Sales Channels

7.4.2 PD-1 and PD-L1 Inhibitor Distributors

7.5 PD-1 and PD-L1 Inhibitor Customer Analysis

8 PD-1 and PD-L1 Inhibitor Market Dynamics

8.1 PD-1 and PD-L1 Inhibitor Industry Trends

8.2 PD-1 and PD-L1 Inhibitor Market Drivers

8.3 PD-1 and PD-L1 Inhibitor Market Challenges

8.4 PD-1 and PD-L1 Inhibitor Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Merck

Regeneron Pharmaceuticals

List of Tables

Table 1. Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global PD-1 and PD-L1 Inhibitor Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global PD-1 and PD-L1 Inhibitor Market Competitive Situation by Manufacturers in 2024

Table 4. Global PD-1 and PD-L1 Inhibitor Sales (Tons) of Key Manufacturers (2020-2025)

Table 5. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2020-2025)

Table 6. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market PD-1 and PD-L1 Inhibitor Average Price (US$/Ton) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of PD-1 and PD-L1 Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Product Type & Application

Table 12. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global PD-1 and PD-L1 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Inhibitor as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global PD-1 and PD-L1 Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global PD-1 and PD-L1 Inhibitor Sales by Region (2020-2025) & (Tons)

Table 18. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2020-2025)

Table 19. Global PD-1 and PD-L1 Inhibitor Sales by Region (2026-2031) & (Tons)

Table 20. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2026-2031)

Table 21. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2020-2025)

Table 23. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2026-2031)

Table 25. North America PD-1 and PD-L1 Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America PD-1 and PD-L1 Inhibitor Sales by Country (2020-2025) & (Tons)

Table 27. North America PD-1 and PD-L1 Inhibitor Sales by Country (2026-2031) & (Tons)

Table 28. North America PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America PD-1 and PD-L1 Inhibitor Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe PD-1 and PD-L1 Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2020-2025) & (Tons)

Table 32. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2026-2031) & (Tons)

Table 33. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region (2020-2025) & (Tons)

Table 37. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region (2026-2031) & (Tons)

Table 38. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America PD-1 and PD-L1 Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2020-2025) & (Tons)

Table 42. Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2026-2031) & (Tons)

Table 43. Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2020-2025) & (Tons)

Table 47. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2026-2031) & (Tons)

Table 48. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global PD-1 and PD-L1 Inhibitor Sales (Tons) by Type (2020-2025)

Table 51. Global PD-1 and PD-L1 Inhibitor Sales (Tons) by Type (2026-2031)

Table 52. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2020-2025)

Table 53. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2026-2031)

Table 54. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Type (2020-2025)

Table 55. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Type (2026-2031)

Table 56. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2020-2025)

Table 57. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2026-2031)

Table 58. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Type (2020-2025)

Table 59. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Type (2026-2031)

Table 60. Global PD-1 and PD-L1 Inhibitor Sales (Tons) by Application (2020-2025)

Table 61. Global PD-1 and PD-L1 Inhibitor Sales (Tons) by Application (2026-2031)

Table 62. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2020-2025)

Table 63. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2026-2031)

Table 64. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Application (2020-2025)

Table 65. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Application (2026-2031)

Table 66. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2020-2025)

Table 67. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2026-2031)

Table 68. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Application (2020-2025)

Table 69. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Application (2026-2031)

Table 70. Merck Company Information

Table 71. Merck Description and Business Overview

Table 72. Merck PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 73. Merck PD-1 and PD-L1 Inhibitor Product

Table 74. Merck Recent Developments/Updates

Table 75. Bristol-Myers Squibb Company Information

Table 76. Bristol-Myers Squibb Description and Business Overview

Table 77. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 78. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product

Table 79. Bristol-Myers Squibb Recent Developments/Updates

Table 80. Pfizer Company Information

Table 81. Pfizer Description and Business Overview

Table 82. Pfizer PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 83. Pfizer PD-1 and PD-L1 Inhibitor Product

Table 84. Pfizer Recent Developments/Updates

Table 85. Sanofi Company Information

Table 86. Sanofi Description and Business Overview

Table 87. Sanofi PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 88. Sanofi PD-1 and PD-L1 Inhibitor Product

Table 89. Sanofi Recent Developments/Updates

Table 90. Regeneron Pharmaceuticals Company Information

Table 91. Regeneron Pharmaceuticals Description and Business Overview

Table 92. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 93. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product

Table 94. Regeneron Pharmaceuticals Recent Developments/Updates

Table 95. Roche Company Information

Table 96. Roche Description and Business Overview

Table 97. Roche PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 98. Roche PD-1 and PD-L1 Inhibitor Product

Table 99. Roche Recent Developments/Updates

Table 100. AstraZeneca Company Information

Table 101. AstraZeneca Description and Business Overview

Table 102. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 103. AstraZeneca PD-1 and PD-L1 Inhibitor Product

Table 104. AstraZeneca Recent Developments/Updates

Table 105. Bristol Myers Squibb Company Information

Table 106. Bristol Myers Squibb Description and Business Overview

Table 107. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 108. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product

Table 109. Bristol Myers Squibb Recent Developments/Updates

Table 110. Hengrui Medicine Company Information

Table 111. Hengrui Medicine Description and Business Overview

Table 112. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 113. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product

Table 114. Hengrui Medicine Recent Developments/Updates

Table 115. Beigene Company Information

Table 116. Beigene Description and Business Overview

Table 117. Beigene PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 118. Beigene PD-1 and PD-L1 Inhibitor Product

Table 119. Beigene Recent Developments/Updates

Table 120. Innovent Biologics Company Information

Table 121. Innovent Biologics Description and Business Overview

Table 122. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 123. Innovent Biologics PD-1 and PD-L1 Inhibitor Product

Table 124. Innovent Biologics Recent Developments/Updates

Table 125. Junshi Biosciences Company Information

Table 126. Junshi Biosciences Description and Business Overview

Table 127. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 128. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product

Table 129. Junshi Biosciences Recent Developments/Updates

Table 130. Akeso Company Information

Table 131. Akeso Description and Business Overview

Table 132. Akeso PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 133. Akeso PD-1 and PD-L1 Inhibitor Product

Table 134. Akeso Recent Developments/Updates

Table 135. Alphamab Oncology Company Information

Table 136. Alphamab Oncology Description and Business Overview

Table 137. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 138. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product

Table 139. Alphamab Oncology Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. PD-1 and PD-L1 Inhibitor Distributors List

Table 143. PD-1 and PD-L1 Inhibitor Customers List

Table 144. PD-1 and PD-L1 Inhibitor Market Trends

Table 145. PD-1 and PD-L1 Inhibitor Market Drivers

Table 146. PD-1 and PD-L1 Inhibitor Market Challenges

Table 147. PD-1 and PD-L1 Inhibitor Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

Table 151. Authors List of This Report

List of Figures

Figure 1. Product Picture of PD-1 and PD-L1 Inhibitor

Figure 2. Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global PD-1 and PD-L1 Inhibitor Market Share by Type: 2024 & 2031

Figure 4. Monoclonal Antibody Product Picture

Figure 5. Bispecific Antibody Product Picture

Figure 6. Global PD-1 and PD-L1 Inhibitor Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global PD-1 and PD-L1 Inhibitor Market Share by Application: 2024 & 2031

Figure 8. Lung Cancer

Figure 9. Stomach Cancer

Figure 10. Breast Cancer

Figure 11. Rectal Cancer

Figure 12. Others

Figure 13. Global PD-1 and PD-L1 Inhibitor Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global PD-1 and PD-L1 Inhibitor Market Size (2020-2031) & (US$ Million)

Figure 15. Global PD-1 and PD-L1 Inhibitor Sales (2020-2031) & (Tons)

Figure 16. Global PD-1 and PD-L1 Inhibitor Average Price (US$/Ton) & (2020-2031)

Figure 17. PD-1 and PD-L1 Inhibitor Report Years Considered

Figure 18. PD-1 and PD-L1 Inhibitor Sales Share by Manufacturers in 2024

Figure 19. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest PD-1 and PD-L1 Inhibitor Players: Market Share by Revenue in PD-1 and PD-L1 Inhibitor in 2024

Figure 21. PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global PD-1 and PD-L1 Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2020-2031)

Figure 24. North America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2020-2031)

Figure 25. United States PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2020-2031)

Figure 28. Europe PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2020-2031)

Figure 29. Germany PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2020-2031)

Figure 36. China PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. China Taiwan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Southeast Asia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2020-2031)

Figure 44. Latin America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2020-2031)

Figure 45. Mexico PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2020-2031)

Figure 50. Turkey PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of PD-1 and PD-L1 Inhibitor by Type (2020-2031)

Figure 54. Global Revenue Market Share of PD-1 and PD-L1 Inhibitor by Type (2020-2031)

Figure 55. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Type (2020-2031)

Figure 56. Global Sales Market Share of PD-1 and PD-L1 Inhibitor by Application (2020-2031)

Figure 57. Global Revenue Market Share of PD-1 and PD-L1 Inhibitor by Application (2020-2031)

Figure 58. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Application (2020-2031)

Figure 59. PD-1 and PD-L1 Inhibitor Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Chrysalis Oil Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26N13078

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Eucommia Ulmoides Extract Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-3L13782

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global MRSA Drugs Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26S13718

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Ferrous Citrate Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-16S12875

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions